I give Niagen Bioscience, Inc. a hold rating. The company has a cash-rich balance sheet with no debt and high-quality earnings. Shareholders have already faced 47.5% dilution since 2016, and there ...

Detailed price information for Tuhura Biosciences Inc (HURA-Q) from The Globe and Mail including charting and trades.

TuHURA Biosciences remains a high-risk investment due to severe cash constraints and imminent dilution risk despite progress in its immunotherapy pipeline. HURA's phase 3 trial for IFx-Hu2.0 in ...

Cogent Biosciences recently reported detailed primary analysis data from its PEAK Phase 3 trial, showing that bezuclastinib plus sunitinib significantly improved progression-free survival and ...

MBX Biosciences recently reported full 12-week Phase 2 Avail trial results and one-year open-label extension data for once-weekly canvuparatide in adults with chronic hypoparathyroidism, showing ...

Investing.com - H.C. Wainwright lowered its price target on Lexaria Bioscience (NASDAQ:LEXX) to $4.00 from $5.00 on Tuesday, while maintaining a Buy rating on the stock. Currently trading at $0.90, ...

Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional grant to the ...

Jade Biosciences ( (JBIO) ) has provided an announcement.